Oncotarget: Scaling the Heights of Modern Science in Cancer Treatment Drugs

Oncotarget is a monthly open access peer-reviewed medical journal that covers all the aspects of oncology research topics. The journal was launched in 2010 with Andrei V. Gudkov of the Roswell Park Cancer Institute and Mikhail Blagosklonny as its editors-in-chief. Mikhail Blagosklonny received his Medical Doctorate (M.D) in internal medicine and doctorate (Ph.D.) in cardiology & experimental medicine from the First Pavlov State Medical University-St. Petersburg; a Russian medical University. Oncotarget is also available on Dove Press.

Mikhail was selected to the Associate Professor of Medicine at the New York Medical College, Valhalla, in 2002. He previously served as a Senior Scientist in Albany, New York, at the Ordway Research Institute. Mikhail held this post till 2009 when he was later chosen as an Oncology Professor at Roswell Park Cancer Institute.

Mikhail’s research areas of interests include targeted cancer and cancer therapies that protect normal human cells from harm, as well as the fundamental aging mechanisms (biogerontology) and anti-aging drugs. Oncotarget made its name while covering oncology.

Blagosklonny’s Oncotarget Journal on Cancer Treatments

In 2011, The National Cancer Institute (NCI) announced 24 challenging questions on cancer. Some of these inquiries received some response in the National Cancer Institute and provoked views on cancer as published in the journal’s review. The questions varied from why many cancer cells die when abruptly deprived oncogene, a type of encoded protein. Can patient survival be extended by using advances that maintain static tumors? Why are several spread cancers healed by chemotherapy alone? Can we expand various methods to test cancer interventions for cancer prevention or treatment swiftly? Can we utilize our aging knowledge to enhance treatment or prevention of cancer? What is the method by which several drugs frequently and continually used for other signs safeguard against cancer? How does obesity increase the risk of cancer?

Mikhail has devoted separate subchapters to answer each of the mentioned questions in the quest to cure or prevent the spread of cancer cases. He expected the questions from a broad perspective to be provocative, numerous, and diverse. In his answers, Mikhail chose and combined the last three questions as a single problem to all correlated, age-related diseases such as cancer and obesity. The research areas all lead to the use of conventional drugs to prevent and treat cancer.

Follow Oncotarget journal on Twitter.